

# Prescription of oral anticoagulants and antiplatelets for stroke prophylaxis in atrial fibrillation: nationwide time series ecological analysis

Jianhua Wu <sup>1,2†</sup>, Eman S. Alsaeed <sup>2,3†</sup>, James Barrett<sup>4</sup>, Marlous Hall<sup>2,3</sup>, Campbell Cowan<sup>5</sup>, and Chris P. Gale<sup>2,3,5\*</sup>

<sup>1</sup>School of Dentistry, University of Leeds, Leeds, UK; <sup>2</sup>Leeds Institute for Data Analytics, University of Leeds, Leeds, UK; <sup>3</sup>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Worsley Building, Level 11, Clarendon Way, Leeds LS2 9JT, UK; <sup>4</sup>PRIMIS, Division of Primary Care, University of Nottingham, Nottingham, UK; and <sup>5</sup>Department of Cardiology, Leeds General Infirmary, Leeds, UK

Received 4 March 2020; editorial decision 24 April 2020; accepted after revision 27 April 2020; online publish-ahead-of-print 10 August 2020

## Aims

To investigate trends in the prescription of oral anticoagulants (OACs) and antiplatelet agents for atrial fibrillation (AF).

## Methods and results

Prescription data for 450 518 patients with AF from 3352 General Practices in England, was obtained from the GRASP-AF registry, 2009–2018. Annualized temporal trends for OAC and antiplatelet prescription were reported according to eligibility based on stroke risk (CHADS<sub>2</sub> or CHA<sub>2</sub>DS<sub>2</sub>-VASc scores  $\geq 1$  or  $>2$ , respectively). From 2009 to 2018, the prevalence of AF increased from 1.6% [95% confidence interval (CI) 1.5–1.7%] to 2.4% (2.3–2.5%), and for those with AF the proportion prescribed OAC increased from 47.6% to 75.0% ( $P$ -trend  $< 0.001$ ; relative risk 1.57, 95% CI 1.55–1.60) and for antiplatelet decreased from 37.4% to 9.2% ( $P$ -trend  $< 0.001$ ). In early-years (2009–2013), eligible patients aged  $\geq 80$  years were less likely to be prescribed OAC than patients aged  $< 80$  years [odds ratio (OR) 0.55, 95% CI 0.51–0.59 for CHADS<sub>2</sub> $\geq 1$  in 2009] (all  $P$ -trends  $< 0.001$ ). This ‘OAC prescription gap’ reduced over the study period (OR 0.93, 0.90–0.96 in 2018). Whilst the prescription of direct oral anticoagulant (DOAC) as a proportion of all OAC increased from 0.1% (95% CI 0.0–0.2%) in 2011 to 58.8% (58.4–59.2%) in 2018, it was inversely associated with patient age ( $P$ -trend  $< 0.001$ ) and their risk of stroke.

## Conclusion

Between 2009 and 2018, in England, the use of OAC for stroke prophylaxis in AF increased, with DOAC accounting for over half of OAC uptake in 2018. Despite a reduction in the OAC-prescription gap, a new paradox exists relating to DOAC prescription for the elderly and those at higher risk of stroke.

## Keywords

Oral anticoagulation • Atrial fibrillation • Stroke • Direct oral anticoagulants • Antiplatelet

## Introduction

Approximately one-third of ischaemic strokes are associated with atrial fibrillation (AF).<sup>1</sup> Such strokes are of importance because they are largely preventable with oral anticoagulation (OAC).<sup>2</sup> To that end, recent international guidelines for clinical practice have lowered

the threshold for the use of OAC in stroke prophylaxis among patients with AF, and have emphasized their use in preference to antiplatelet drugs (AP).<sup>3,4</sup>

With the advent of direct oral anticoagulants (DOACs), which when compared with warfarin reduce the frequency of cerebral haemorrhage and intracranial bleeding, there has been a progressive

\* Corresponding author. Tel: +44 (0)113 343 8905. E-mail address: c.p.gale@leeds.ac.uk

† The first two authors contributed equally to the study.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

### What's new?

- This contemporary population-wide 10-year study provides good evidence for system-wide improvements in the use of oral anticoagulants (OAC) for stroke prophylaxis in atrial fibrillation (AF).
- Between 2009 and 2018, in England, the use of OAC for stroke prophylaxis in AF increased, with direct oral anticoagulant (DOAC) accounting for over half of OAC uptake in 2018.
- Despite a reduction in the OAC-prescription gap, a new paradox exists relating to DOAC prescription for the elderly and those at higher risk of stroke.

increase in the use of OAC for stroke prophylaxis in AF.<sup>5–7</sup> Our earlier research reported the temporal decline in hospitalized AF-related stroke in England (that occurred in the face of an increasing prevalence of AF), and postulated that this may be due to the uptake of OAC.<sup>7</sup> We have also noted a system-wide risk-treatment paradox, whereby older patients with AF less frequently were prescribed OAC (and more frequently offered APs).<sup>8</sup> This is resonated in the international literature,<sup>9,10</sup> and of concern given the increasing prevalence of AF associated with an ageing population.<sup>3,11</sup>

In the UK, evidence for the underutilization of OAC has led to national quality improvement initiatives to improve their uptake.<sup>8,12</sup> The Guidance on Risk Assessment and Stroke Prevention in Atrial Fibrillation (GRASP-AF) was implemented as a national service improvement tool and accompanying registry in 2009 to improve OAC uptake, and in 2012 changes to the national Quality and Outcomes Framework (QOF)<sup>13</sup> incentivized General Practitioners to use OAC in preference to APs. In addition, the National Institute for Health and Care Excellence (NICE) has emphasized the importance of patient choice with respect to type of OAC for stroke prophylaxis in AF in patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$ .<sup>14</sup> Given this and the paucity of population-based information about the use of DOACs and, in particular, their use among the elderly, we used the nationwide GRASP-AF registry of 3352 General Practices in England between 2009 and 2018 to study changes in OAC and AP prescription for stroke prophylaxis in AF.

## Methods

### The GRASP-AF registry

The GRASP-AF tool, launched in 2009, was developed to help General Practitioner's assess the risk of AF-related stroke and guide the effective management of patients with AF.<sup>8</sup> The tool is based on the use of Morbidity Information Query and Export SynTax (MIQUEST), a common query process integrated by all of the primary care computer systems in England. Originally, the GRASP-AF tool was parameterized around the CHADS<sub>2</sub> risk evaluation system but further updated from 2011 to fit the CHA<sub>2</sub>DS<sub>2</sub>-VASc score which gives a better stratification of lower-risk patients. Participating General Practices voluntarily upload their prospective GRASP-AF data onto the central server registry. Each upload contains a snapshot of all eligible patients with AF and their prescription at

that practice at that time. The GRASP-AF registry was set up and is managed by PRIMIS (Primary Care Information Services) at the University of Nottingham.

### Patients with atrial fibrillation

Patients with current, or history of, AF or atrial flutter were identified through a comprehensive set of Read codes ([Supplementary material online, Table S1](#)) from the GRASP-AF registry, 1 January 2009 to 31 December 2018.<sup>8,14</sup> For each patient, the risk of stroke was estimated from the components and associated coefficients of the CHADS<sub>2</sub> score, namely each patient's age, history of heart failure, hypertension, diabetes, and stroke or transient ischaemic attack (see Read codes in [Supplementary material online, Table S1](#)).<sup>15</sup> From 2011, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score was also incorporated into the GRASP-AF tool by including vascular disease as well as the CHADS<sub>2</sub> score's revised coefficients.<sup>16,17</sup>

Each General Practice recorded patient-level data using the GRASP-AF tool that included information about the prescription of OAC and AP therapy by CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores. Data are summarized at the level of the General Practice and uploaded onto a central server by participating practices. For this study, the uploaded data were aggregated by age bands (<30, 30–49, 50–64, 65–79, and  $\geq 80$  years), prescription of OAC or AP, and the data extracted separately by CHADS<sub>2</sub> or CHA<sub>2</sub>DS<sub>2</sub>-VASc score (according to period of study). Patient data from the risk scores were then aggregated at four levels of stroke risk: 0, 1, 2, and  $>2$ .<sup>7</sup> Based on European Society of Cardiology (ESC) Clinical Practice Guidelines for AF,<sup>4</sup> OAC therapy is recommended for men with a stroke CHA<sub>2</sub>DS<sub>2</sub>-VASc risk  $\geq 1$  and women with a stroke risk  $\geq 2$ . Population data relating to each General Practice were aggregated by the same age bands. Although General Practices may upload data multiple times in any given year, only the first upload of the year for each practice was extracted for this study.


### Oral anticoagulation and antiplatelet therapy

Patients with AF within the last 6 months were identified through Read codes ([Supplementary material online, Table S2](#)). Their anticoagulant uptake was determined and included both vitamin K antagonists (VKAs) (warfarin, acenocoumarol, and phenindione) and non-VKA including dabigatran and rivaroxaban (both first introduced in the UK in 2008), apixaban (first introduced in the UK in 2011) and edoxaban (first introduced in the UK in 2015). Data for AP prescription (aspirin, clopidogrel, and dipyridamole) was similarly extracted ([Supplementary material online, Table S2](#)). Patients issued AP therapy were counted only if they were not co-prescribed OAC.

### Statistical analysis

The prevalence of AF was calculated by year and age using the total number of patients with AF as a proportion of the total number of patients registered at each General Practices. The use of OAC and AP therapy was derived from the number of patients with AF prescribed OAC or AP therapy divided by the number of patients with AF across each CHADS<sub>2</sub> or CHA<sub>2</sub>DS<sub>2</sub>-VASc score.

To determine the temporal trends of OAC and AP prescription, we used generalized linear models with a logit link and binomial distribution and plotted results using cubic splines. Sequential models were fitted which regressed the proportion of patients with AF prescribed OAC or AP therapy on age band and year as well as an age by year interaction to model the effect of aged-related temporal changes in prescription and compared with the null model. Each model was weighted by the size of



**Figure 1** The temporal prevalence of AF, 2009–2018. AF, atrial fibrillation.

the General Practice. Separate models were applied to patients with AF stratified by their respective stroke risk score. Analyses were performed for patients with the CHADS<sub>2</sub> scores across 2009–2018 and patients with the CHA<sub>2</sub>DS<sub>2</sub>-VASc score across 2011–2018.

A permutation test was performed to assess differences between the growth of the prescription curves of a DOAC and VKA among patients with a recorded CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>18</sup> The growth differences were compared according to CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and age bands. Analyses were undertaken using R version 3.6.0 (<http://www.r-project.org/>). In line with National Health Service (NHS) research governance arrangements, ethical approval was not required for this analysis.

## Results

Between 2009 and 2018, 3352 individual General Practices provided a total of 5968 uploads into the GRASP-AF database (the median number of uploads each year 501, interquartile range 407–568). From the first upload per General Practice, there were an estimated 450 518 patients with AF from a total of 24 644 210 people, and over the study period the prevalence of AF was 1.8% [95% confidence interval (CI) 1.7–1.9%], which increased from 1.6% (1.5–1.7%) in 2009 to 2.4% (2.3–2.5%) in 2018 ( $P$ -trend < 0.001, *Figure 1*). The prevalence of AF was stable for people aged <65 years ( $P$ -trends not

significant), but increased over time for those aged 65–79 and ≥80 years ( $P$ -trend, both <0.001) (*Figure 1*, [Supplementary material online, Table S3](#)).

## Temporal trends in oral anticoagulant and antiplatelet prescription: CHADS<sub>2</sub>, 2009–2018

Overall, the proportion of patients with AF who were prescribed OAC or AP was 59.4% and 25.3%, respectively, with proportions varying across practices. Over the study period, the variability (interquartile range) across practices in the proportion of AF prescribed OAC and AP therapy decreased from 17.6% to 10.5% and from 15.0% to 4.0% for OAC and AP therapy, respectively ([Supplementary material online, Table S4](#)). In the earlier years (2009–2013), the prescribing variation was wider by CHADS<sub>2</sub> score, however, this variation reduced to similar level across the CHADS<sub>2</sub> scores from 2015 onwards ([Supplementary material online, Table S4](#)).

In total, 58.5% of the AF population had a CHADS<sub>2</sub> score of ≥2 and 84.2% ≥1. There was a year-on-year increase in the prescription of OAC with increasing CHADS<sub>2</sub> score (*Table 1*). For all patients with AF, the proportion prescribed an OAC increased from 47.6% in 2009 to 75.0% in 2018 ( $P$ -trend < 0.001; relative risk 1.57, 95% CI

**Table 1** Temporal trends of the prescription of oral anticoagulants and antiplatelets for patients with AF by CHADS<sub>2</sub> score, 2009–2018

Year	Number of patients with AF (prevalence, %) <sup>a</sup>	Oral anticoagulant, n (%) <sup>b</sup>					Antiplatelet, n (%) <sup>b</sup>					Total
		CHADS <sub>2</sub> score					CHADS <sub>2</sub> score					
		0	1	2	>2	Total	0	1	2	>2	Total	
2009	16 158 (1.6)	999 (36.2)	2138 (47.5)	2330 (50.8)	2231 (51.8)	7698 (47.6)	791 (28.7)	1710 (38.0)	1796 (39.1)	1752 (40.6)	6049 (37.4)	
2010	58 256 (1.7)	3543 (34.6)	7426 (46.7)	8392 (51.0)	8599 (54.9)	27 960 (48.0)	3118 (30.5)	6026 (37.9)	6333 (38.5)	5876 (37.5)	21 353 (36.7)	
2011	163 101 (1.8)	8768 (33.9)	20 487 (47.3)	25 562 (53.5)	26 777 (57.9)	81 594 (50.0)	7840 (30.3)	16 023 (37.0)	17 183 (36.0)	16 089 (34.8)	57 135 (35.0)	
2012	161 747 (1.8)	8432 (33.4)	20 389 (48.3)	26 484 (55.4)	28 030 (60.4)	83 335 (51.5)	7739 (30.6)	15 526 (36.8)	16 555 (34.6)	15 275 (32.9)	55 095 (34.1)	
2013	61 055 (1.8)	3142 (33.3)	7827 (51.5)	10 651 (58.8)	11 571 (63.1)	33 191 (54.4)	2660 (28.2)	5186 (34.1)	5669 (31.3)	5565 (30.4)	19 080 (31.3)	
2014	52 102 (2.0)	2897 (35.4)	7442 (56.9)	9946 (64.3)	10 435 (67.9)	30 720 (59.0)	1855 (22.7)	3686 (28.2)	3874 (25.1)	3896 (25.4)	13 311 (25.5)	
2015	82 403 (2.2)	5289 (39.8)	13 185 (63.4)	16 994 (70.3)	17 981 (74.4)	53 449 (64.9)	2194 (16.5)	4354 (20.9)	4693 (19.4)	4640 (19.2)	15 881 (19.3)	
2016	96 063 (2.1)	6469 (43.0)	16 047 (67.1)	20 647 (73.4)	22 460 (77.6)	65 623 (68.3)	1895 (12.6)	3904 (16.3)	4454 (15.8)	4587 (15.8)	14 840 (15.4)	
2017	106 037 (2.1)	7382 (44.3)	18 637 (70.7)	23 885 (77.0)	25 850 (80.8)	75 754 (71.4)	1582 (9.5)	3233 (12.3)	3798 (12.2)	4093 (12.8)	12 706 (12.0)	
2018	88 016 (2.4)	6237 (46.4)	16 374 (74.7)	20 951 (80.6)	22 420 (84.0)	65 982 (75.0)	1020 (7.6)	2089 (9.5)	2463 (9.5)	2551 (9.6)	8123 (9.2)	

AF, atrial fibrillation.

<sup>a</sup>Number (%) represents AF prevalence in overall population.<sup>b</sup>n (%) represents the proportion of oral anticoagulant/antiplatelet prescribing amongst patients with AF and corresponding CHADS<sub>2</sub> score.

1.55–1.60), whereas the proportion prescribed an AP decreased from 37.4% to 9.2% over the same period ( $P$ -trend < 0.001). Moreover, a pattern of an increase in OAC and decrease in AP prescription was evident across each of the CHADS<sub>2</sub> scores (Table 1).

Although OAC prescription increased over time, in the earlier years (2009–2013) patients aged  $\geq 80$  years were less likely to be prescribed OAC than patients aged <80 years, for all CHADS<sub>2</sub> scores  $\geq 1$  (Figure 2). However, results from general linear models stratified by CHADS<sub>2</sub> score found that, each year, the ‘OAC prescription gap’ between patients aged  $\geq 80$  and <80 years reduced annually by 1.2% (95% CI 0.2–2.2%) for CHADS<sub>2</sub> = 1, 1.6% (95% CI 0.9–2.3%) for CHADS<sub>2</sub> = 2, and 1.8% (95% CI 1.3–2.4%) for CHADS<sub>2</sub> >2. In parallel, the ‘AP prescription gap’ for the same age bands reduced by a similar magnitude (Figure 2). At the end of the study in 2018, there was an OAC-prescription gap between age  $\geq 80$  years and age <80 years for CHADS<sub>2</sub> >2 [odds ratio (OR) 0.63, 95% CI 0.58–0.67] and CHADS<sub>2</sub> = 2 (OR 0.79, 95% CI 0.74–0.84), but not for CHADS<sub>2</sub> = 1 (OR 0.95, 95% CI 0.89–1.02).

### Temporal trends in oral anticoagulant and antiplatelet prescription: CHA<sub>2</sub>DS<sub>2</sub>-VASc, 2011–2018


Overall, 62.5% of patients with AF were prescribed OAC (45.8% VKA and 16.5% DOAC), and 21.9% of patients with AF were prescribed AP therapy (Table 2 and Supplementary material online, Table S5).

In total, 84.7% of the AF population had a CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$  and 94.5%  $\geq 1$ . There was a year-on-year increase in the prescription of OACs with increasing CHA<sub>2</sub>DS<sub>2</sub>-VASc score (Table 2). For all patients with AF, the proportion prescribed OAC increased from 49.6% in 2011 to 75.0% in 2018 ( $P$ -trend < 0.001, Table 2), whereas the proportion prescribed an AP decreased from 34.6% to 9.2% over the same period ( $P$ -trend < 0.001, Supplementary material online, Table S5). Even so, at the end of 2018 <10% of General Practices achieved levels of 80% OAC prescription for eligible patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$  and age  $\geq 80$  years.

Although OAC prescription did increase over time, for the earlier years (2009–2013) patients aged  $\geq 80$  years were less likely to be prescribed OAC than patients aged <80 years, for all CHA<sub>2</sub>DS<sub>2</sub>-VASc scores >2 (Figure 3). Nonetheless, analyses stratified by CHA<sub>2</sub>DS<sub>2</sub>-VASc score found that, each year, the ‘OAC prescription gap’ between patients aged  $\geq 80$  and <80 years reduced annually by 1.7% (95% CI 1.2–2.3%) for CHA<sub>2</sub>DS<sub>2</sub>-VASc score >2, with a corresponding reduction in the magnitude of the ‘AP prescription gap’ for the same age bands (Figure 3). At the end of the study in 2018, there was an OAC-prescription gap between age  $\geq 80$  years and age <80 years for CHA<sub>2</sub>DS<sub>2</sub>-VASc >2 (OR 0.74, 95% CI 0.71–0.77), but not for CHA<sub>2</sub>DS<sub>2</sub>-VASc = 2 (OR 0.90, 95% CI 0.81–1.00).

### Prescription of direct oral anticoagulants

Overall, 26.4% of patients prescribed OAC received a DOAC. Direct OAC prescription increased from 0.1% in 2011 to 58.8% of all OAC in 2018 ( $P$ -trend < 0.001, Table 2), while VKA prescription decreased from 99.6% to 41.1% over the same period ( $P$ -trend < 0.001, Table 2).



**Figure 2** The temporal trend of oral anticoagulant and antiplatelet prescription for patients with AF by age band and CHADS<sub>2</sub> score, 2009–2018. AF, atrial fibrillation.

The prescription of DOACs increased at a faster rate among patients with a lower CHA<sub>2</sub>DS<sub>2</sub>-VASc score (pairwise comparisons after adjustment for multiple comparison, all *P*-values <0.001 *Figure 4*). Furthermore, for patients with the same CHA<sub>2</sub>DS<sub>2</sub>-VASc score, patients aged <65 years were more likely to be prescribed a DOAC than patients in older age bands (all *P*-values < 0.01 after adjustment for multiple comparison, *Figure 5*). At the end of the study in 2018, there was a DOAC-prescription gap between age <65 and 65–79 years for CHA<sub>2</sub>DS<sub>2</sub>-VASc score =1 (OR 0.79, 95% CI 0.72–0.87); a DOAC-prescription gap for CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 (OR 0.74, 95% CI 0.69–0.80 for age 65–79 years; OR 0.70, 95% CI 0.65–0.75 for age ≥80 years) compared with prescription for patients age <65 years.

## Discussion

This population-based, multicentre, 10-year study of the use of OAC for stroke prophylaxis for patients with AF found that the prescription of OAC for patients with AF at high risk of stroke increased by nearly 60%. By 2018, about three quarters of all patients recorded in primary care in England with AF and a CHADS<sub>2</sub> or CHA<sub>2</sub>DS<sub>2</sub>-VASc

score ≥2 were receiving OAC. This increase in OAC prescription occurred at a time of a dramatic rise in the prescription of DOACs. Beyond the decline in the use of AP therapy, however, there was evidence for General Practice level variation in the use of OAC for stroke prophylaxis, which although decreased over the study period was still evident in 2018 and suggests that the potential to reduce the risk of AF-related stroke has not been fully realized. In addition, there was a clear ‘OAC prescription gap’ among the elderly, which was evident for the prescription of DOAC.

Overall, the prescription of OAC for patients with AF increased by nearly 30% over 10 years; in the UK before 2011 <50% of patients with AF were prescribed OAC. The use of OAC for stroke prophylaxis in AF increased from circa the publication of the 2010 ESC Clinical Practice Guidelines for the management of AF, which recommended the use of OAC for all patients at moderate to high risk of stroke (CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥ 1),<sup>3</sup> and a 2012 recommendation that the prescription of AP drugs was no longer suitable for stroke prophylaxis in low-risk patients with AF, unless patients refused or were ineligible for any type of OAC.<sup>19</sup> Yet, other factors may have contributed to the change in prescribing habits including quality improvement initiatives such as deployment of the nationwide GRASP-AF tool, heightened physician

**Table 2** Temporal trend of the prescription of DOACs and VKA for patients with AF by CHA<sub>2</sub>DS<sub>2</sub>-VASC score, 2011–2018

Year	Number of AF patients prescribed with OAC (%)	DOAC					VKA					Total
		CHA <sub>2</sub> DS <sub>2</sub> -VASC score					CHA <sub>2</sub> DS <sub>2</sub> -VASC score					
		0	1	2	>2	Total	0	1	2	>2	Total	
2011	20 575 (49.6)	1 (0.2)	3 (0.2)	3 (0.1)	15 (0.1)	22 (0.1)	614 (99.2)	1543 (99.5)	3267 (99.5)	15 062 (99.6)	20 486 (99.6)	
2012	72 253 (51.3)	7 (0.4)	48 (0.9)	79 (0.7)	273 (0.5)	407 (0.6)	1858 (98.5)	5227 (97.8)	10 925 (98.4)	53 165 (98.6)	71 175 (98.5)	
2013	33 177 (54.4)	36 (4.5)	92 (4.0)	164 (3.3)	697 (2.8)	989 (3.0)	756 (95.3)	2222 (95.4)	4832 (96.2)	24 227 (96.8)	32 037 (96.6)	
2014	30 720 (59.0)	84 (12.9)	238 (12.0)	501 (10.6)	2087 (8.9)	2910 (9.5)	566 (86.8)	1737 (87.8)	4205 (89.1)	21 233 (90.9)	27 741 (90.3)	
2015	53 449 (64.9)	264 (25.5)	845 (23.8)	1636 (19.3)	7380 (18.3)	10 125 (18.9)	769 (74.3)	2704 (76.0)	6808 (80.3)	32 885 (81.4)	43 166 (80.8)	
2016	65 623 (68.3)	618 (47.7)	1753 (39.5)	3666 (35.7)	15 556 (31.4)	21 593 (32.9)	677 (52.3)	2680 (60.3)	6595 (64.2)	33 977 (68.5)	43 929 (66.9)	
2017	75 754 (71.4)	929 (63.9)	2779 (54.9)	5933 (49.4)	25 688 (44.9)	35 329 (46.6)	524 (36.0)	2264 (44.7)	6044 (50.4)	31 477 (55.0)	40 309 (53.2)	
2018	65 865 (75.0)	871 (74.9)	2881 (66.5)	6357 (61.6)	28 635 (57.2)	38 744 (58.8)	289 (24.8)	1446 (33.4)	3944 (38.2)	21 370 (42.7)	27 049 (41.1)	

AF, atrial fibrillation; DOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; VKA, vitamin K antagonist.

awareness and familiarity with the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASC scores, and the availability from 2011 of alternatives to VKA in the form of DOACs.

Specifically, we found that the age-dependent 'OAC prescription gap' reduced by nearly 20%—a reduction which was consistent across the moderate to high risk of stroke patients (determined either by CHADS<sub>2</sub> or CHA<sub>2</sub>DS<sub>2</sub>-VASC score), and by the end of the study in 2018 OAC prescribing was less age-dependent. However, there remained inequalities in the delivery of care, evidenced by variation in the use of OAC across General Practices.<sup>20–22</sup> Such variation suggests that the opportunity to improve the uptake of OAC for stroke prophylaxis among patients with AF has not been accomplished. In contrast, we found that the prescription of OAC among patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASC of 0 increased over the study period, suggesting that in addition to the underuse of OAC among higher-risk patients, there is evidence for overuse of OAC for stroke prophylaxis in AF for those in whom it may not be appropriate. We can only speculate as to why this may be the case, and that it relates to a misperception of the balance of benefit and harm in this low-risk group. That is, patients with AF who are at low risk of stroke may be inappropriately prescribed OAC because they are felt to be at low risk of bleeding events associated with OAC and the risk of stroke if they do not receive OAC when in fact their relative gain from stroke prophylaxis is negligible.

We found that the prescription of DOACs increased substantially over the 10 years of study, to account for nearly 60% of all OAC prescription at the end of 2018. Direct OACs have been shown to be superior to VKA in stroke prevention, and carry similar overall bleeding risk.<sup>23–26</sup> Despite this, we found that for all higher stroke risk categories, the uptake of DOACs was inversely associated with age and estimated risk of stroke, and at the end of the study there was a reduced, but persisting 'DOAC prescription gap'. That is, there is good evidence to support the notion of an on-going risk-treatment paradox for the use of DOACs in the elderly, with higher stroke risk patients over the age of 80 years less frequently prescribed DOACs than VKA overall. It is plausible that for DOACs there remains risk-adverse strategy among healthcare professionals, again because of the misperception that OAC is associated with bleeding events in the elderly and that this outweighs the perceived benefit of stroke prevention.

## Limitations

For this study, the GRASP-AF registry included 3352 individual General Practices, which represents about half of all General Practices in England. Despite this large sample size, data are uploaded voluntarily at each General Practice, and therefore may not be fully representative of the population as a whole.<sup>8</sup> The proportion of patients aged ≥65 years in the analytical cohort, is slightly higher than that reported by the Office for National Statistics estimate for England (17.4% vs. 16.5%), again highlighting potential limitations in generalizability. The prevalence of AF was calculated according to the diagnostic code in the GRASP-AF tool, and in doing so may incur an improper estimation. Furthermore, some information such as sex and history of bleeding or other contra-indications to OAC is not separately available in the GRASP-AF data extraction, which prevents any inference about the justification for prescribing patterns. This registry data did not specify whether the prescription was for patients



**Figure 3** The temporal trend of oral anticoagulant and antiplatelet prescription for patients with AF by age band and CHA<sub>2</sub>DS<sub>2</sub>-VASc score, 2011–2018. AF, atrial fibrillation.

with newly diagnosed AF, we were unable to investigate whether the reducing prescription gap was due to therapy switching, but recognize that there is likely to be a legacy effect of chronic VKA prescription and that this might affect age bands differently. We acknowledge the limitations of the ecological study design, and given the observational nature of the study that causation is not implied.

## Conclusion

This contemporary population-wide 10-year study provides good evidence for system-wide improvements in the use of OAC for stroke prophylaxis in AF. The pronounced uptake in the use of DOACs in this population is likely to have been a driver in improvement in overall OAC uptake and to have contributed, moreover, to a marked reduction in the historical age-related OAC risk-treatment paradox. Nonetheless, this study suggests that a new paradox, relating to DOAC for the elderly and higher stroke risk, exists. Local and national strategies are now required to eliminate such inequity in care so that reductions in potentially preventable AF-related strokes may be achieved.

## Supplementary material

Supplementary material is available at *Europace* online.

## Funding

M Hall is funded by the Wellcome Trust (Grant Reference: 206470/Z/17/Z). J Wu is supported by the National Institute for Health Research (NIHR) infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.


**Conflict of interest:** none declared.

## Data availability

The data would be available to access upon ethical approval.

## References


1. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. *Stroke* 2014; **45**:2599–605.
2. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. *Lancet* 2016; **388**:806–17.



**Figure 4** Temporal trend of the prescription of DOACs and VKA for patients with AF by CHA<sub>2</sub>DS<sub>2</sub>-VASc score, 2011–2018. AF, atrial fibrillation; DOAC, direct OAC; OAC, oral anticoagulants; VKA, vitamin K antagonists.

- Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Europace* 2010;**12**: 1360–420.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;**18**:1609–78.
- Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. *Thromb Haemost* 2016;**115**:31–9.
- Gadssboll K, Staerk L, Fosbol EL, Sindet-Pedersen C, Gundlund A, Lip GYH et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. *Eur Heart J* 2017;**38**:899–906.
- Cowan JC, Wu J, Hall M, Orłowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. *Eur Heart J* 2018;**39**:2975–83.
- Cowan C, Healicon R, Robson I, Long WR, Barrett J, Fay M et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. *Heart* 2013;**99**:1166–72.
- Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). *Eur Heart J* 2006;**27**: 1954–64.
- Waldo AL, Becker RC, Tapson VF, Colgan KJ, Committee NS. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. *J Am Coll Cardiol* 2005;**46**:1729–36.
- Perera KS, Vanassche T, Bosch J, Swaminathan B, Mundl H, Giruparajah M et al. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined Source Global Registry. *Stroke* 2016;**47**: 2197–202.
- Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GY. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. *Br J Gen Pract* 2012;**62**:e710–7.
- Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. *Am J Med* 2010;**123**: 638–45.e4.
- National Institute for Health and Care Excellence. Atrial fibrillation: management. Clinical guideline [CG180]. 2014. <https://www.nice.org.uk/guidance/cg180>.
- Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;**285**:2864–70.





**Figure 5** Temporal trends of the prescription of DOACs for patients with AF by age band, 2011–2018. AF, atrial fibrillation; DOAC, direct oral anticoagulants; VKA, vitamin K antagonists.

16. Saliba W, Gronich N, Barnett-Griness O, Rennert G. Usefulness of CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study. *Am J Med* 2016;**129**:843–9.
17. Kirchhof P. Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines. *Heart* 2017;**103**:729–31.
18. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S et al.; for the GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. *PLoS One* 2013;**8**:e63479.
19. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Europace* 2012;**14**:1385–413.
20. Robson J, Homer K, Ahmed Z, Antoniou S. Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study. *Br J Gen Pract* 2018;**68**:e551–8.e8.
21. Group FS, Leizorovicz A, Cohen A, Guenoun M, Mismetti P, Weisslinger N. Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. *Pharmacoepidemiol Drug Saf* 2007;**16**:32–8.
22. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000–2009. *Heart* 2013;**99**:127–32.
23. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;**361**:1139–51.
24. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;**369**:2093–104.
25. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;**383**:955–62.
26. Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ* 2017;**359**:j5058.